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ABSTRACT 
Background 
Inherited metabolic disorders associated with medullary nephrocalcinosis are 
rare conditions, the most studied being Dent disease, familial 
hypomagnesemia with hypercalciuria and nephrocalcinosis, and renal 
hyperoxaluria. More recently, loss-of-function mutations of the CYP24A1 
gene, encoding for the Vitamin D-24-hydroxylase, were found to cause 
nephrocalcinosis in both infants and adults. The aim of this study was to identify 
the genetic cause of an Israeli-Arab boy from a consanguineous family with 
severe nephrocalcinosis and kidney insufficiency. 
 
Subjects and Methods 
Clinical and biochemical data of the proband and family members were 
obtained both from previous medical charts and from recent evaluation. 
Genomic DNA was isolated from peripheral blood cells. The coding sequence 
and splice-sites of candidate genes (CYP24A1, CYP27B1, FGF23, KLOTHO, 
SLC34A3, and SLC34A1) were amplified by PCR and sequenced directly. 
Functional studies were performed in Xenopus laevis oocytes and in transfected 
opossum kidney (OK) cells.  
 
Results 
Our patient was identified with nephrocalcinosis in utero and at the age of 16.5 years 
had kidney insufficiency but no bone disease. Genetic analysis revealed a novel 
homozygous missense mutation, R215Q, in SLC34A1, which encodes the renal 
sodium-phosphate cotransporter NaPiIIa. Functional studies of the R215Q mutant 
3 
 
NaPiIIa revealed reduced transport activity in Xenopus laevis oocytes and increased 
intracellular cytoplasmic accumulation in opossum kidney cells. 
Conclusion 
Our findings show that dysfunction of the human NaPiIIa may cause severe renal 
calcification that eventually reduces kidney function, rather than complications of 
phosphate loss.  
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Short Summary 
We identified a patient with nephrocalcinosis in utero due to a novel homozygous 
missense mutation in the renal sodium-phosphate cotransporter NaPiIIa. Our findings 
show that dysfunction of the human NaPiIIa may lead to severe renal calcification 
that eventually reduces kidney function, rather than complications of phosphate loss.  
 
 
 
 
 
 
INTRODUCTION 
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Nephrocalcinosis, defined as renal parenchyma calcification, is caused by a 
number of conditions, which involve dysregulation of calcium homeostasis 
and may lead to acute or chronic kidney injury [1]. 
Inherited metabolic disorders associated with nephrocalcinosis with or without 
nephrolithiasis are rare conditions, the most studied are Dent disease, familial 
hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) and 
renal hyperoxaluria (PH). More recently, loss-of-function mutations of the  
CYP24A1 gene, encoding for the Vitamin D-24-hydroxylase, were discovered 
to be a main cause of severe infantile hypercalcemia, hypercalciuria and 
nephrocalcinosis [2],[3]. 
NaPiIIa is a member of the SLC34 family of sodium-driven phosphate co-
transporters, mainly expressed in the apical brush border membrane of the 
kidney proximal tubule [4]. Extensive studies in murine models have shown 
that either complete deletion of the SLC34A1 gene or homozygosity loss-of-
function NaPiIIa mutations reduce renal reabsorption of phosphate, alter 
phosphate homeostasis and lead to renal calcification [5],[6]. 
However, until recently the clinical effects of NaPiIIa mutations in human were 
controversial. It has remained unclear whether human heterozygous 
mutations may be the cause of kidney stones [7, 8]. The clinical findings in the 
first reported homozygous NaPiIIa mutation in human included Fanconi 
syndrome and bone disease without hypercalciuria or nephroalcinosis [9], 
while another paper described hypercalcemia and nephrocalcinosis without 
skeletal dysfunction [10]. Recent publications strengthen the involvement of 
SLC34A1 in hypercalcemia and kidney stones. A genome-wide-association-
study among 5419 kidney stone cases found an association to a rare 
missense variant in SLC34A1 [11]. Halbritter et. al. reported that out of 272 
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kidney stone patients screened for mutations in 30 genes suspected to be 
associated with kidney stones, one patient was found  with compound 
heterozygous mutations in slc34a1 [12]. Finally, Schlingmann et. al. reported 
causative mutations in SLC34A1 in cases of idiopathic infantile hypercalcemia 
[13]. 
We studied an Israeli-Arab adolescent from a consanguineous family with 
severe nephrocalcinosis and kidney failure, and identified by the candidate 
gene approach a homozygous NaPiIIa missense mutation, p.Arg215Gln, as 
underlying the disease. The proband's mutation is described in Schlingmann 
et. al. ([13], supplement material), but functional analysis was not performed.  
Here we show that the potential pathogenic effect of this mutation is 
suggested by in silico analysis and is verified by functional studies in Xenopus 
Laevis oocytes and in opossum kidney cells. 
 
SUBJECTS AND METHODS 
Subjects  
We studied an Israeli-Arab adolescent boy with nephrocalcinosis and kidney 
insufficiency, and several members of his extended family. Clinical data were 
obtained both from previous medical charts and from recent evaluation. The 
study protocol was approved by the institutional review board of the Chaim 
Sheba Medical Center, Israel.  Informed consent for genetic analysis and 
medical evaluation was obtained from all studied subjects.  Consent for the 
minors was given by their parents.   
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Candidate gene sequencing 
The history of hypocalcemia and nephrocalcinosis along with increased 1,25 
dihydroxyvitamin D3 and suppressed PTH levels prompted us to evaluate 
genes associated with calcium and phosphate homeostasis. 
Genomic DNA was isolated from peripheral blood cells applying the 
ArchivePure DNA Blood Kit (5 PRIME, USA) according to the manufacturer’s 
instructions. The coding sequence and splice-sites of CYP24A1, CYP27B1, 
FGF23, KLOTHO, SLC34A3, and SLC34A1 were amplified by PCR using 
intronic primers. Primers for CYP24A1 were previously described [3]. 
Sequence of the other primers will be provided on demand.  All PCR products 
were sequenced directly (ABI Prism 3100; Applied Biosystems, Foster City, 
CA). 
 
Preparation of Plasmid Constructs 
Full-length hSLC34A1 subcloned either into the KSM oocyte expression 
vector or into pEGFP-C1 (Clontech) [14] was used as template to generate 
the p.Arg215Gln mutant. The mutation was introduced by site-directed 
mutagenesis using the Quick-Change kit (Stratagene). Mutagenic primers 
were designed using the Stratagene web based QuickChange® Primer 
Design software Program. The plasmid containing the generated mutation 
was isolated using QIAprep Spin Miniprep (Qiagen, 27106) and the correct 
mutation was confirmed by sequencing (Microsynth, Balgrist, Switzerland). 
One clone from each construct was used for the experiments. 
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Cell culture and transient transfections 
Opossum kidney cells (clone 3B/2) were cultured in DMEM / Ham's F-12 
medium (1:1) supplemented with 10% fetal calf serum, 2 mM glutamine, 20 
mM Hepes and 50 IU/ml penicillin/streptomycin as previously reported [15]. 
Cells were plated on coverslips in 12 multiwell plates (TPP), and cultures 
were transfected with either wild type (WT) hNaPiIIa fused to pEGFP-C1 
vector or with the mutant described above. Cultures were transfected at about 
70% confluency by an overnight incubation in 500 µl OPTIMEM (GIBCO, 
31985-047) containing 1 μg of DNA and 3 μl of Lipofectamine™ 2000 
Reagent (Invitrogen, 11668-019). We performed two independent 
experiments, each in duplicates or triplicates. 
Actin staining and confocal microscopy of OK cells 
Upon expression of clear patches of WT hNaPiIIa signal (two to three days 
after transfection), cells were fixed with paraformaldehyde and permeabilised 
with saponin as described previously [16]. Thereafter, actin was stained by 
incubation with Texas Red®-X phalloidin (Invitrogen) diluted 1:500. After 
incubation for 30 min in the dark, cells were washed three times with 
PBS/saponin and once with PBS. The coverslips were then mounted on 
microscope slides using DakoGlycergel® Mounting Medium. The subcellular 
final locations of the transfected cotransporters were analyzed by Confocal 
Laser Scanning Microscopy (Leica SP2) using a 63x oil immersion objective 
at the Center for Microscopy and Image Analysis at the University of Zurich. 
 
Expression of hNaPiIIa and the p.Arg215Gln mutant in Xenopus Laevis 
oocytes 
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Female X. laevis frogs were purchased from Xenopus Express (France) or 
African Xenopus Facility (R. South Africa). Portions of ovaries were surgically 
removed from frogs anesthetized in MS222 (tricainemethansulphonate) and 
cut in small pieces. Oocytes were treated for 45 min with collagenase (crude 
type 1A) 1 mg/ml in 100 Na solution (see below; without Ca2+) in presence of 
0.1 mg/ml trypsin inhibitor type III-O. Healthy stage V-VI oocytes were 
selected, maintained at 16°C in modified Barth’s solution (in mM: 88 NaCl, 1 
KCl, 0.41 CaCl2, 0.82 MgSO4, 2.5 NaHCO3, 2 Ca(NO3)2, 7.5 HEPES, pH 7.5 
adjusted with Tris and supplemented with 5 mg/l doxycyclin and 5 mg/l 
gentamicin). All animal procedures were conducted in accordance with the 
Swiss Cantonal and Federal legislation relating to animal experimentation.  
Capped cRNA was synthesized in vitro using Megascript T3 kit (Ambion) in 
the presence of cap analog (New England Biolabs). Oocytes were injected 
with 50 nl of cRNA (200 ηg/μl). Experiments were performed 3 days after 
injection. Non-injected control oocytes (NI), oocytes expressing hNaPiIIa WT 
and the p.Arg215Gln mutant (6-10 oocytes/group) were first allowed to 
equilibrate in 100 Na solution (in mM: 100 NaCl, 2 KCl, 1.8 CaCl2, 10 HEPES, 
pH 7.4 adjusted with Tris) without tracer. After aspiration of this solution, 
oocytes were incubated in 100 Na solution containing 1 mM cold Pi (added 
from a 1 M K2HPO4/ KH2PO4 stock premixed to give pH 7.4) and 
32Pi (specific 
activity 10 mCi mmol-1 Pi, Perkin Elmer). Uptake proceeded for 10 min, then 
oocytes were washed 4 times with ice-cold 0 Na solution (Na replaced by 
choline) containing 2 mM Pi and lysed individually in 2% SDS for 10 min 
before addition of the scintillation cocktail. The amount of radioactivity in each 
oocyte was measured by scintillation counting (Tri-Carb 29000TR, Packard).  
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All voltage clamp experiments were performed using a two-electrode voltage 
clamp (TEC-10CX, NPI, Tamm, Germany). Oocytes were impaled with 
microelectrodes filled with 3 M KCl, with a typical resistance of <1 MΩ. The 
temperature of the recording chamber was monitored using a thermistor 
probe (TS-2, NPI, Tamm, Germany) placed close to the oocyte. The 
temperature of the recording chamber and incoming superfusate were 
regulated using Peltier cooling elements driven by a continuous feedback 
controller (TC-10, NPI Tamm, Germany). Data acquisition was performed 
using a 1440 Digidata (Molecular Devices Corp, USA). For recordings at 
constant holding potential, currents were acquired at >20 samples/s and 
filtered at 10 Hz. Faster sampling rates (up to 20 k samples/s) were used for 
voltage step recordings with filtering (digital and analog) adjusted accordingly. 
Steady-state currents were obtained using a protocol in which membrane 
voltage steps were made from the holding potential (Vh)=−60 mV, to test 
voltages in the range −140 to +40 mV in 20 mV increments. The steady-state 
Pi-dependent current (IPi) was obtained by subtracting control traces (in 
100Na solution) from the corresponding traces in the presence of Pi. Data 
was rejected if contaminated by endogenous Cl- -currents. Experiments were 
performed with 0.1 and 1 mM in the presence of 100 mM Na or in a solution 
where 50 mM NaCl had been replaced by 50 mM LiCl. 
 
 
 
RESULTS 
Clinical characteristics of the patient and family 
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A 16.5-year-old adolescent was referred to our clinic at the age of 12 years for 
evaluation of congenital nephrocalcinosis. He is the first child of healthy 
consanguineous parents of Israeli-Arab origin (fig. 1a) with other three healthy 
siblings.  A paternal aunt and grandmother and a maternal uncle were 
previously diagnosed with nephrolithiasis, the aunt had undergone 
extracorporeal lithotripsy. No cases of end-stage renal failure in the family 
were reported. 
 The patient was born at term in another hospital. Medullary nephrocalcinosis 
was suspected on fetal ultrasound and confirmed on neonatal and later 
repeated sonographic exams.  
The child developed normally and was asymptomatic, but nephrocalcinosis 
persisted on repeated ultrasound examinations with normal sized kidneys 
growing along the 30-50th percentile for age.  However, on the most recent 
imaging a left kidney lower pole stone was found along with cortical thinning 
and prominent diffuse medullary calcifications (fig. 1b). 
Physical examination during the follow-up was normal, with growth and blood 
pressure - within normal range for age. Up to the age of 16.5 years the patient 
did not show any sign of rickets or any other bone disease.  
Laboratory investigations in our clinic revealed normal serum calcium and 
phosphorus levels, slightly depressed PTH levels- 12.3 – 16.5 ng/L (normal 
15 – 65ng/L) and elevated  1,25 dihydroxyvitamin D: 166 – 230 pmol/L 
(normal 39-160 pmol/L) with normal  25 hydroxyvitamin D levels.  Urinary 
calcium/creatinine was within low-normal range: 0.05 – 0.1 in repeated 24-
hour urine collections.  No phosphaturia was found with TRP (tubular 
reabsorption of phosphate) values of 92%-96.7% on repeat samples and 
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TmP/GFR of 2.9- 4.02 mg/dl. Citrate excretion was slightly depressed with 
normalization after lemon juice supplement.  Urinary oxalate, uric acid and 
cystine excretion were also normal. Normal urinary lysozyme concentration 
was found and normal albumin/creatinine ratio. GFR estimated by creatinine 
clearance was decreased to 70 ml/min/1.73m2. 
Unfortunately, we could not retrieve detailed data on the relevant laboratory 
parameters before the referral to our clinic, especially for the neonatal period 
when, according to the parents and the family physician, he was hospitalized 
due to hypercalcemia and nephrocalcinosis already present. The only relevant 
findings were serum calcium of 12.4 mg/dl and phosphorus 3.2 mg/dl at the 
age of 5 months (normal range for age: calcium 8.8-10.8 mg/dl, phosphorus 
3.8-6.5 mg/dl) and hypercalciuria in the range of 0.25-0.35 calcium/creatinine 
found on urine samples at the ages of 6-10 years (normal range for age: 
calcium/creatinine < 0.2). 
 We also evaluated nine family members, including the three subjects with a 
history of nephrolithiasis. All of them had normal kidney function, normal 
serum calcium and phosphorus values and normal calcium/creatinine and 
phosphorus/creatinine ratio in urine (data not shown). 
Genetic analysis of candidate genes 
We first examined several genes that are known to be involved in the 
regulation of calcium and vitamin D handling and have been linked to 
nephrocalcinosis or kidney stones. We sequenced the genes CYP24A1, 
CYP27B1, KLOTHO and FGF23 and found no mutation. We then sequenced 
SLC34A1 and SLC34A3, the genes coding for the renal phosphate renal 
transporters NaPiIIa and NaPiIIc. In SLC34A3, in which mutations are known 
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to cause hypophosphatemic rickets with hypercalciuria and 
hyperphosphaturia, we identified a heterozygous insertion - 
c.967_968insAGCTCCTGGCCG - that was also present in the healthy father 
(data not shown). 
In SLC34A1 we identified a novel homozygous missense mutation, 
p.Arg215Gln (fig. 1c). Several family members, with or without a history of 
nephrolithiasis, were found to be heterozygous carriers of this mutation. 
However, in the proband's grandmother, who reported having kidney stones in 
the past no mutation was found (fig. 1a).  
 
In Silico studies 
The new mutation detected in the SLC34A1 gene (hg19:chr5:176814874) was 
examined in various large data sets to exclude it from being a polymorphism. 
A variant in this position was not evident in the 1000 genomes project [17] or 
in the ESP (ESP http://evs.gs.washington.edu/EVS/) project (zero alleles). In 
addition, a variant in this position does not appear in the Exac browser which 
aggregates information of more than 60,000 individuals (Exome Aggregation 
Consortium - ExAC, Cambridge, MA, http://exac.broadinstitute.org) either.  
Finally, we examined 100 normal Israeli-Arab genomes, and did not find even 
a single mutated allele. 
Furthermore, the mutation we describe replaces an amino acid highly 
conserved among the members of the SLC34 family (fig. 2a).  
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The mutation is located in the last nucleotide of the sixth exon. As such, it 
might affect the splicing donor motif. cDNA analysis of the proband and his 
father showed that this is not the case (data not shown).   
No experimental structure has been solved for this protein, so a careful 
structural insight regarding this mutation is missing. No structure for a close 
homolog is available so it is also difficult to construct a confident model. 
However, Fenollar-Ferrer et al. [18] constructed a model based on the 
structure of the Vibrio cholerae Na+ dicarboxylate transporter, which shares 
overall sequence identity of around 15% with human SLC34A1. They suggest 
inverted structural repeats in the overall topology, like often found in other 
families of transporters. The model suggests that the mutation is located in 
the first structural repeat unit, in the N-terminal domain, in or close to the 
cytoplasmic side of the membrane (fig. 2b). 
 
Functional studies 
Transport activity of mutant NaPiIIa 
Expression of human wild type NaPiIIa in Xenopus laevis oocytes induced 
sodium-dependent phosphate uptake whereas oocytes not injected with 
cRNA showed only negligible phosphate uptake. Moreover, the R215Q 
NaPiIIa transporter mediated some phosphate transport, significantly higher 
than in non-injected oocytes but also significantly less than in wild type 
expressing oocytes (Figure 3a).  
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Electrophysiological characterization of mutant NaPiIIa 
We assessed the electrogenic behavior of the R215Q mutant by functional 
expression in Xenopus oocytes using the standard two electrode voltage 
clamp (TEVC) technique. We used our standard screening assay [19] to 
compare the normalized response to 0.1 mM Pi (in 100Na); 50 mM Na (1 mM 
Pi) and 50 mM Na+50 MM Li (1 mM Pi) (Fig 3b). Compared with the WT 
hNaPi-IIa (fig. 3b left panel), the mutant showed a more curvilinear I-V in 
response to 1 mM Pi, suggesting that the removal of charge at 215 had 
affected the voltage dependence (Fig 3b right panel).  The response to 0.1 
mM Pi (100Na+0.1Pi) was suppressed compared with the WT suggesting that 
the mutagenesis had marginally compromised the apparent affinity for Pi 
(K0.5
Pi ) Based on this two state assay, we predict that this would amount to an 
approximately 2-fold increase in K0.5
Pi (see supplementary figure, Fennolar 
[19]). Moreover, whereas for the WT, the normalized responses to a 50% 
reduction in external Na+ (50 Na+1Pi) or replacement of 50% external Na+ 
ions with Li+ ions (50Na50Li+1Pi) were similar, R215Q showed a slightly 
increased response with respect to the Li+ substitution.  
 
Expression in renal proximal tubule cells 
EGFP-tagged wild type NaPiIIa was transiently transfected into the renal 
opossum kidney cell line, a model for the proximal tubule. Wild type NaPiIIa 
localized to the luminal brush border membrane as indicated by the yellow 
color resulting from colocalization with actin (stained in red) expressed in 
apical microvilli (fig. 3c left panel). Lateral views of the same cell indicate that 
a substantial part of NaPiIIa is found in the apical membrane as suggested by 
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only faint green intracellular staining. The R215Q mutant localized also in part 
to the brush border membrane and colocalized there with actin (yellow 
overlay). However, in contrast to the wild type situation, distinct intracellular 
green staining was observed suggesting partial retention of the mutant protein 
(3c right panel).  
 
DISCUSSION 
We report that a homozygous missense mutation in the sodium-phosphate 
co-transporter NaPiIIa, p.Arg215Gln, is the likely cause of nephrocalcinosis 
and kidney insufficiency in our patient. The causative role of this mutation in 
the pathogenesis of our patient's kidney disease is supported by the following 
findings: 1. among the 9 family members studied only the homozygous 
proband had nephrocalcinosis and kidney insufficiency. 2. The nucleotide 
variant that we identified was not found in the general population, and was 
absent from 200 alleles of healthy unrelated Israeli-Arab individuals. 3. The 
mutated amino acid, the arginine in position 215, is highly conserved through 
evolution and in the SLC34 family of phosphate transporters (fig. 2a). 4. In 
silico studies suggest that this mutation results in a significant change of both 
the size and the charge in this position, and is deleterious to the protein. 5. 
The results of In Vitro expression studies indicate that the single amino acid 
change found in our patient suffices to reduce phosphate transport and 
localization in the apical membrane. 
Our findings are in agreement with those found in animal models of reduced 
or absent NaPiIIa function.  In mice, a homozygous single amino acid 
substitution in NaPiIIa altered phosphate (Pi) homeostasis and led to renal 
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calcification [5]. NaPiIIa knock-out mice show increased urinary Pi excretion, 
hypophosphatemia, elevated serum 1,25 dihydroxyvitamin D  levels, 
decreased serum PTH levels, hypercalcemia and hypercalciuria [6].  
In humans, however, the impact of heterozygous NaPiIIa mutations in the 
formation of kidney stones is controversial and the clinical effects of 
homozygous mutations vary. The first study on the role of NaPiIIa in human 
kidney disease and bone demineralization was published by Prie et al in the 
NEJM, 2002 [7]. In this report two out of 20 patients with urolithiasis, bone 
deformation and hypophosphatemia were found to be heterozygous carriers 
of NaPiIIa missense mutations (A48F; V147M). Functional analysis in 
Xenopus Laevis oocytes demonstrated altered function and dominant 
negative effects of the mutated transporter. These findings were later 
challenged by two other studies: Virkki et al examined the function of the 
same two mutations and found similar apical expression of mutated and WT 
proteins in OK cells. Furthermore, oocyte studies excluded a dominant 
negative effect of both mutations [14]. Lapointe et al examined several 
NaPiIIa variants found in a cohort of 98 pedigrees with a history of multiple 
calcium kidney stones including non-synonymous mutations and a truncation 
deletion. No difference was found between WT and heterozygous carriers in 
terms of calcium and phosphorus excretion, so the authors concluded that the 
variants described had no clinical significance [8].  
Interestingly, several reports described either hypophosphatemia [20] or 
infantile hypercalcemia and nephrocalcinosis [21] in patients with Sotos 
syndrome, caused by a heterozygous microdeletion on chromosome 5q35, 
which removes both the NSD1 and NaPiIIa genes. Sotos syndrome is 
characterized by bone overgrowth and mental retardation due to 
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haploinsufficiency of the NSD1 gene. The calcium and phosphorus disorders 
were assumed to be the consequence of NaPiIIa haploinsufficiency, but it is 
not clear whether other changes due to the deletion also contribute to the 
phenotype.  
The first report of a homozygous NaPiIIa mutation in human described two 
Israeli-Arab siblings with hypophosphatemic rickets, hypercalciuria, highly 
elevated 1,25 dihydroxyvitamin D  levels and partial Fanconi syndrome. Both 
carried an in-frame duplication of 21 bp that was shown in Xenopus Laevis 
oocytes and opossum kidney cells to prevent transport of the protein to the 
cell membrane, thereby leading to complete loss-of function of the transporter 
[9]. The occurrence of Fanconi syndrome in the context of SLC34A1 mutation 
is not clear. In two different mouse models of SLC34A1 deficiency due to 
genetic deletion or compound heterozygous mutations no signs of Fanconi 
syndrome have been observed [22]. Suggested explanations include a 
specific toxic tubular effect of this particular mutation due to intracellular 
accumulation or an additional mutation in this consanguineous family [23]. 
Rajagopal et al reported another mutation in SLC34A1, p.Arg495His, in two 
siblings who presented with hypercalciuria and nephrocalcinosis [10]. 
Interestingly, according to our model, the p.Arg495His mutation was predicted 
to fall in a similar context as our mutation, within a cytoplasmic loop. This 
mutation is located in a less quality region of our model so we cannot 
verify/contradict their conclusion. 
Screening a cohort of patients with kidney stones, Halbritter et al identified 
one patient compound heterozygous for the p.Val91_Ala97del and 
p.Arg512Cys mutations. Of note, the p.Val91_Ala97del had been identified 
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previously by Lapointe et al [8], and suggested to be non-pathogenic whereas 
no information is available on the functional consequences of the 
p.Arg512Cys mutation [12].  
Most recently, Schlingmann et.al. reported on 16 cases of infantile idiopathic 
hypercalcemia with causative autosomal recessive  mutations in slc34a1. 
Functional studies of some of the mutations demonstrated disturbed 
trafficking to the plasma membrane as well as loss of phosphate transport 
activity.  The mutation that we evaluated, p.Arg215Gln, is predicted to be 
harmful to the protein by most predictive tools. Since the mutation affects a 
charged residue and might be located in a predicted transmembrane domain, 
it could be expected to alter helical packing and/or mobility of the transporter 
in the membrane. Our in vitro results suggest indeed reduced transport 
function of the p.Arg215Gln mutation in the oocyte assay and impaired 
trafficking of the mutant protein to the plasma membrane in OK cells. This 
concurs with the functional results of Schlingmann et.al., although the 
p.Arg215Gln showed only partial reduction in phosphate transport, as 
opposed to the loss of phosphate transport in other mutants shown by 
Schlingmann et.al.  
 The results of the electrophysiological characterization suggest that the R→ 
Q substitution at position 215 had indeed altered the voltage-dependent 
kinetics and the interaction of cations with the transporter. This in turn would 
lead to the observed reduced apparent affinity for Pi. Given that under 
physiological conditions, the renal Pi at pH 7.4 is far in excess of K0.5
Pi, we 
would conclude that the mutation had marginal effects on the transport 
behavior in vivo. However, we cannot exclude the possibility of a somewhat 
compromised contribution of NaPiIIa to overall proximal tubular Pi influx at low 
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Pi below or close to the reported WT K0.5
Pi for human NaPiIIa of ~100 M.  
The reduced apical expression may account for most of the observed 
phenotype in vivo reducing the overall capacity of the kidney to conserve 
phosphate.   
Based on animal data, mutations in slc34a1 leading to complete loss of 
function or gene deletion would be expected to cause renal phosphate loss. 
However, the mutation described here may exert only a mild impairment of 
renal phosphate reabsorption. Moreover, the increase in 1,25 
dihydroxyvitamin D may fully compensate for the defect in NaPiIIa by 
upregulating NaPiIIc, at the expense of increased intestinal calcium 
absorption and subsequent renal hypercalciuria, facilitating nephrocalcinosis. 
Alternatively, the contribution of NaPiIIa to renal phosphate reabsorption may 
decrease by age in contrast to the situation in mice. 
Unlike the phenotype in humans with mutation of the second kidney 
phosphate transporter, NaPiIIc (SLC34A3), hypophosphatemic rickets is not a 
frequent feature in patients with SLC34A1 mutations. Whether heterozygous 
NaPiIIa mutations can cause kidney stones remains to be proven. Our family 
included 6 heterozygous carriers of the mutation of which only 2 had a history 
of kidney stones. The proband's grandmother reported kidney stones although 
she carried two wild type SLC34A1 alleles. Thus, other hereditary or 
environmental factors contributed to the development of kidney stones in this 
family, and maybe also in previously reported heterozygous carriers of 
different SLC34A1 variants [7],[8]. Kidney stone formation on the background 
of heterozygous SLC34A1 mutations may provide an example of gene-
environment interactions and remain to be deciphered in more detail. 
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Conclusion 
We present severe nephrocalcinosis and renal insufficiency in a patient 
carrying a homozygous (p.Arg215Gln) mutation of the renal phosphate 
transporter NaPiIIa causing partial loss of function.  
The prominent effect of this mutation is increased serum calcium and renal 
calcification, rather than complications of phosphate loss. Our interpretation 
for these findings is that the mutation described here may exert only a mild 
impairment of renal phosphate reabsorption, probably compensated by 
upregulation of NaPiIIc due to increased 1,25  dihydroxyvitamin D. The 
elevation of 1,25  dihydroxyvitamin D results in increased intestinal calcium 
absorption, which leads to the severe nephrocalcinosis seen in our patient.  
Thus, mutations in SLC34A1 may increase the risk for hypercalciuria and  
nephrocalcinosis, eventually leading to renal insufficiency, and must be 
considered in young patients with such symptoms. 
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Figure legends 
Figure 1 
A. Family tree: The arrow points to the proband. White icons depict 
subjects not evaluated. Grey and black are the WT and mutant allele 
respectively. * indicate patients with a history of nephrolithiasis. 
B. A sonogram of the probands kidney at the age of 15 years. 
C. Sequence chromatogram showing WT, homozygote and 
heterozygote subjects for the p.Arg215Gln mutation. 
Figure 2 
Analysis of the conservation and structural context of the R215 residue. 
A. R215 is located at a conserved site within a conserved domain. 
B. The predicted location of R215 residue according to Enollar-Ferrer 
model is shown [15].  
C. Secondary structure and accessibility predictions for SLC34A1. The 
mutation is predicted to fall on the border between membrane helix 
and cytoplasmic loop and on the border between a buried part of 
the protein and an exposed part. 
Figure 3 
A.  Phosphate transport activity of wild-type and mutant p.Arg215Gln-
hNaPiIIa. 32Phosphate uptakes were performed in Xenopus oocytes 3 
days after injection of cRNA encoding hNaPiIIa. Data are from two 
independent batches of oocytes, each 8-10 oocytes; NI, non injected; 
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wt, wild-type. All data were normalized to the transport activity of 
wildtype hNaPiIIa. 
B. Normalised electrogenic behavior of oocytes expressing the 
human NaPi-IIa WT and mutant R215Q. Data were normalized to the 
response when superfusing with 100Na+1Pi at -100 mV. Data from WT 
were modified and redrawn from Fenollar et al 2015. Each data point 
for R215Q is mean±sem of 4-5 cells. 
C. Expression of EGFP-tagged human NaPiIIa cotransporter in 
renal OK cells. Cells were transiently transfected with pEGFP plasmids 
containing either human wild-type or mutant hNaPiIIa, as well as with 
the empty pEGFP plasmid. Confluent cultures were viewed on a 
confocal microscope. Top panels - Focal planes of apical projections. 
Bottom panels - Cross sections. NaPiIIa signal is shown in green, the 
actin staining in red, yellow indicates colocalization of NaPiIIa and actin 
in apical microvilli. 
 



